HealthTree Logo
search more_vert
close
person Sign In / Create Account

Hans-Peter Kiem, MD

Director, Cell and Gene Therapy Program, Clinical Research Division

31 years treating Acute Lymphocytic Leukemia

Clinical Expertise

Leukemia, Acute Lymphoblastic (ALL)

About

Dr. Hans-Peter Kiem is a world-renowned pioneer in stem-cell and gene therapy and in the development of new gene-editing technologies. His focus has been the development of improved treatment and curative approaches for patients with genetic and infectious diseases or cancer. For gene editing, his lab works on the design and selection of enzymes, known as nucleases, which include CRISPR/Cas. These enzymes function as molecular scissors that are capable of accurately disabling defective genes. By combining gene therapy’s ability to repair problem-causing genes and stem cells’ regenerative capabilities, he hopes to achieve cures of diseases as diverse as HIV, leukemia and brain cancer. With preclinical models of HIV, Dr. Kiem and his colleagues have demonstrated that they can modify a key viral entry gene and prevent it from working in transplanted blood stem cells. He also hopes to apply these technologies to cure genetic blood disorders such as Fanconi anemia and sickle cell disease. He is also pioneering in vivo gene therapy approaches to make gene therapy and gene editing more broadly available and accessible to patients and those living with HIV, especially in resource-limited settings.

Location

Fred Hutchinson Cancer Center: Fred Hutch Cancer Ctr, 825 Eastlake Ave E, Seattle, WA 98109, USA

Get the latest thought leadership on Acute Lymphocytic Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Acute Lymphocytic Leukemia Newsletter" for Acute Lymphocytic Leukemia news, life with Acute Lymphocytic Leukemia stories, Acute Lymphocytic Leukemia clinical trials, Acute Lymphocytic Leukemia 101 articles and events with Acute Lymphocytic Leukemia experts.